Ibrutinib for Relapsed or Refractory Mantle Cell Lymphoma

A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

NCT01599949 ·Status: COMPLETED ·Phase: PHASE2

Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL

NCT02419560 ·Status: COMPLETED ·Phase: PHASE1

131I-rituximab for Relapsed or Refractory Follicular or Mantle Cell Lymphoma

NCT01678417 ·Status: UNKNOWN ·Phase: PHASE2

IBER Salvage Treatment Followed by Ibrutinib Maintenance for Relapsed or Refractory PCNSL

NCT04066920 ·Status: UNKNOWN ·Phase: PHASE2

Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma

NCT02242097 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment

NCT02341781 ·Status: COMPLETED

Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults

NCT01809600 ·Status: COMPLETED

Zanubrutinib in the Treatment of Recurrent Refractory Mantle Cell Lymphoma

NCT05486013 ·Status: RECRUITING

Ibrutinib Combined With Bendamustine and Rituximab in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged > 65 Years

NCT05406154 ·Status: UNKNOWN

Ibrutinib in Treating Participants With Untreated High Risk Smoldering Mantle Cell Lymphoma

NCT03282396 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Safety and Efficacy of BKM120 in Relapsed and Refractory NHL

NCT01693614 ·Status: COMPLETED ·Phase: PHASE2

Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies

NCT04994626 ·Status: UNKNOWN ·Phase: PHASE2

A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma

NCT05431179 ·Status: WITHDRAWN ·Phase: PHASE3

Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma

NCT02542514 ·Status: COMPLETED ·Phase: PHASE2

Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL

NCT02682641 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma(MCL)

NCT03616782 ·Status: RECRUITING ·Phase: PHASE2

A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma

NCT02460276 ·Status: COMPLETED ·Phase: PHASE2

A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma

NCT02756247 ·Status: COMPLETED ·Phase: PHASE1

A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type

NCT04414163 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma

NCT02427620 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

NCT01647971 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Bendamustine Plus Rituximab for Mantle Cell Lymphoma: a Multicenter Retrospective Analysis(BR-MCL)

NCT04127916 ·Status: UNKNOWN

Intensified 1st Cycle Rituximab Plus 8th Cycles of R-CHOP Chemotherapy in Patients With Advanced or Bulky CD20+ Diffuse Large B-cell Lymphoma (DLBCL)

NCT01054781 ·Status: COMPLETED ·Phase: PHASE2

Study of Mantle Cell Lymphoma Treatment by RiBVD

NCT01457144 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)

NCT07082686 ·Status: RECRUITING ·Phase: PHASE2